UB Paderborn / Katalog / Suche / in CDI

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

Therapeutic Advances in Chronic Disease, 2022, Vol.13, p.20406223221081605-20406223221081605

2022

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Neurotrophins Biodelivery to CNS: Innovative Approaches for Disease-Modifying Therapy

Frontiers in neuroscience, 2022-05, Vol.16, p.916563-916563

2022

Link zum Volltext

Verfügbarkeit prüfen

Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors

FEBS letters, 2013-08, Vol.587 (15), p.2325-2331

2013

Link zum Volltext

Verfügbarkeit prüfen

Use of Donanemab in Early Symptomatic Alzheimer Disease

JAMA : the journal of the American Medical Association, 2023-12, Vol.330 (23), p.2304

2023

Link zum Volltext

Verfügbarkeit prüfen

Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation

International journal of molecular sciences, 2017-01, Vol.18 (1), p.184-184

2017

Link zum Volltext

Verfügbarkeit prüfen

Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging

Alzheimer's & dementia : translational research & clinical interventions, 2020, Vol.6 (1), p.e12065-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Do anti‐Aβ monoclonal antibodies lower brain plaques in Alzheimer patients through microglia activation?

Alzheimer's & dementia, 2024-03, Vol.20 (3), p.2289-2290

2024

Link zum Volltext

Verfügbarkeit prüfen

Brain Amyloid Deposition in Late-Life Depression

Biological psychiatry (1969), 2021-04, Vol.89 (8), p.e41-e42

2021

Link zum Volltext

Verfügbarkeit prüfen

Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?

Expert opinion on drug discovery, 2020-11, Vol.15 (11), p.1241-1251

2020

Link zum Volltext

Verfügbarkeit prüfen

The β-Secretase BACE1 in Alzheimer’s Disease

Biological psychiatry (1969), 2021-04, Vol.89 (8), p.745-756

2021

Link zum Volltext

Verfügbarkeit prüfen

Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?

Ageing research reviews, 2019-11, Vol.55, p.100948-100948, Article 100948

2019

Link zum Volltext

Verfügbarkeit prüfen

Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?

Expert review of neurotherapeutics, 2019-07, Vol.19 (7), p.599-602

2019

Link zum Volltext

Verfügbarkeit prüfen

Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer’s disease?

Ageing research reviews, 2021-11, Vol.71, p.101420-101420, Article 101420

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular mechanisms of skin wound healing in non-diabetic and diabetic mice in excision and pressure experimental wounds

Cell and tissue research, 2022-06, Vol.388 (3), p.595-613

2022

Link zum Volltext

Verfügbarkeit prüfen

Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?

Alzheimer's & dementia, 2023-01, Vol.19 (1), p.353-368

2023

Link zum Volltext

Verfügbarkeit prüfen

Type 2 Diabetes Mellitus, Platelet Activation and Alzheimer’s Disease: A Possible Connection

Clinical neuropsychiatry, 2022-12, Vol.19 (6), p.370-378

2022

Link zum Volltext

Verfügbarkeit prüfen

Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease: Research outline and call for collaboration

Alzheimer's & dementia, 2023-11, Vol.19 (11), p.5209-5231

2023

Link zum Volltext

Verfügbarkeit prüfen

The [beta]-Secretase BACE1 in Alzheimer's Disease

Biological psychiatry (1969), 2021-04, Vol.89 (8), p.745

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological targeting of the β-amyloid precursor protein intracellular domain

Scientific reports, 2014-04, Vol.4 (1), p.4618, Article 4618

2014

Link zum Volltext

Verfügbarkeit prüfen

Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?

International psychogeriatrics, 2016-07, Vol.28 (7), p.1111-1124

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's Disease

CNS drugs, 2001, Vol.15 (5), p.375-390

IMBIMBO, Bruno Pietro

2001

Link zum Volltext

Verfügbarkeit prüfen

RELATIONSHIP BETWEEN CEREBROSPINAL FLUID (CSF) BIOMARKERS AND COGNITIVE PERFORMANCE OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI) AFTER LONG-TERM TREATMENT WITH CHF5074

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P273-P273

2014

Link zum Volltext

Verfügbarkeit prüfen

O4‐11‐01: RELATIONSHIP BETWEEN CEREBROSPINAL FLUID (CSF) BIOMARKERS AND COGNITIVE PERFORMANCE OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI) AFTER LONG‐TERM TREATMENT WITH CHF5074

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_5), p.P273-P273

2014

Link zum Volltext

Verfügbarkeit prüfen

The γ-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer’s Disease

Journal of molecular neuroscience, 2011-09, Vol.45 (1), p.22-31

2011

Link zum Volltext

Verfügbarkeit prüfen

Toxicity of β-amyloid vaccination in patients with Alzheimer's disease

Annals of neurology, 2002-06, Vol.51 (6), p.794-794

Imbimbo, Bruno Pietro

2002

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

Editorial: Neurotrophins Biodelivery to CNS: Innovative Approaches for Disease-Modifying Therapy

Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors

Use of Donanemab in Early Symptomatic Alzheimer Disease

Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation

Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging

Do anti‐Aβ monoclonal antibodies lower brain plaques in Alzheimer patients through microglia activation?

Brain Amyloid Deposition in Late-Life Depression

Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?

The β-Secretase BACE1 in Alzheimer’s Disease

Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?

Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?

Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer’s disease?

Molecular mechanisms of skin wound healing in non-diabetic and diabetic mice in excision and pressure experimental wounds

Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?

Type 2 Diabetes Mellitus, Platelet Activation and Alzheimer’s Disease: A Possible Connection

Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease: Research outline and call for collaboration

The [beta]-Secretase BACE1 in Alzheimer's Disease

Pharmacological targeting of the β-amyloid precursor protein intracellular domain

Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's Disease

RELATIONSHIP BETWEEN CEREBROSPINAL FLUID (CSF) BIOMARKERS AND COGNITIVE PERFORMANCE OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI) AFTER LONG-TERM TREATMENT WITH CHF5074

O4‐11‐01: RELATIONSHIP BETWEEN CEREBROSPINAL FLUID (CSF) BIOMARKERS AND COGNITIVE PERFORMANCE OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI) AFTER LONG‐TERM TREATMENT WITH CHF5074

The γ-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer’s Disease

Toxicity of β-amyloid vaccination in patients with Alzheimer's disease

Suchergebnisse filtern